195 related articles for article (PubMed ID: 32449226)
1. Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy.
Fujimura T; Kambayashi Y; Tono H; Lyu C; Ohuchi K; Hashimoto A; Aiba S
Dermatol Ther; 2020 Jul; 33(4):e13672. PubMed ID: 32449226
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases.
Blum V; Müller B; Hofer S; Pardo E; Zeidler K; Diebold J; Strobel K; Brand C; Aebi S; Gautschi O
Eur J Dermatol; 2018 Feb; 28(1):78-81. PubMed ID: 29336323
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
5. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma.
Oliveira LJC; Gongora ABL; Barbosa FG; Dos Anjos CH; Munhoz RR
J Immunother Cancer; 2018 Nov; 6(1):130. PubMed ID: 30482243
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy for advanced cutaneous squamous cell carcinoma.
Fitzgerald K; Tsai KK
Semin Cutan Med Surg; 2019 Mar; 38(1):E67-E74. PubMed ID: 31051028
[TBL] [Abstract][Full Text] [Related]
7. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia : a case series and literature review.
Eglmeier J; Debus D; Schultz ES
Eur J Dermatol; 2020 Feb; 30(1):69-71. PubMed ID: 32250263
[No Abstract] [Full Text] [Related]
8. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Hernández-Guerrero T; Doger B; Moreno V
Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
[TBL] [Abstract][Full Text] [Related]
9. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
In GK; Vaidya P; Filkins A; Hermel DJ; King KG; Ragab O; Tseng WW; Swanson M; Kokot N; Lang JE; Menendez L; DeClerck B; Kim G; Hu JC; Terando A; Jadvar H; Ricker C; Miller KA; Peng DH; Wysong A
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1803-1811. PubMed ID: 33210210
[TBL] [Abstract][Full Text] [Related]
10. Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: A review of the literature.
Corneli P; Conforti C; Retrosi C; Vezzoni R; di Meo N; Piccolo V; Farinazzo E; Russo T; Magaton Rizzi G; Giuffrida R; Zalaudek I
Dermatol Ther; 2020 Mar; 33(2):e13250. PubMed ID: 32022968
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
[TBL] [Abstract][Full Text] [Related]
12. Combining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone.
Hsu E; Eton O; Patel AV; Cartun R; Earle JS; Mnayer LO; Kotowitz J; Yu PP
J Drugs Dermatol; 2021 Aug; 20(8):901-904. PubMed ID: 34397194
[TBL] [Abstract][Full Text] [Related]
13. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma.
Noda T; Komune N; Yasumatsu R; Tsuchihashi NA; Tamae A; Matsumoto N; Sato K; Uchi R; Koike K; Wakasaki T; Tanaka R; Nakagawa T
Auris Nasus Larynx; 2020 Oct; 47(5):864-869. PubMed ID: 32446629
[TBL] [Abstract][Full Text] [Related]
15. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
[TBL] [Abstract][Full Text] [Related]
16. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD1 Agents in the Treatment of Cutaneous Squamous Cell Carcinoma.
Niu W; Robertson C; Hilton D
Skinmed; 2022; 20(5):338-342. PubMed ID: 36314696
[TBL] [Abstract][Full Text] [Related]
18. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
19. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp.
Paoluzzi L; Ow TJ
Curr Oncol; 2021 Jan; 28(1):574-580. PubMed ID: 33477979
[TBL] [Abstract][Full Text] [Related]
20. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
